In the early years of the smartphone revolution, the phrase "there’s an app for that" became the defining mantra of a generation. As the Apple App Store and Google’s Android Market flourished, the medical community grew optimistic. Visionaries like cardiologist Eric Topol and physician-innovator Daniel Kraft predicted a seismic shift: a future where digital tools, sensors, and mobile applications would be prescribed by physicians with the same regularity as pharmaceutical pills.
Nearly two decades later, that vision has largely remained in the realm of aspiration. While the FDA has cleared a select few digital therapeutics, the industry has faced a "valley of death" characterized by poor patient engagement and a lack of viable reimbursement models.
Enter Remepy, a startup that is pivoting away from standalone digital medicine. Led by co-founder and co-CEO Dr. Michal Tsur, the company is pioneering a new category of "hybrid drugs"—an innovative fusion that pairs conventional, time-tested pharmaceuticals with AI-driven, app-delivered treatment protocols. With a successful Phase IIa clinical trial for their lead candidate, Hybridopa, now in the books, Remepy is testing the hypothesis that the future of medicine isn’t just digital or chemical—it’s both.
The Convergence of Pharmacology and Digital Intervention
Remepy’s foundational philosophy is a direct critique of the modern, fragmented healthcare system. "Everything we do is built on the understanding that most complex medical conditions are better treated with a multidisciplinary, integrative approach," Dr. Tsur explains.
For many chronic conditions, the standard of care involves a pharmaceutical cornerstone, supplemented by disparate, often uncoordinated, non-pharmaceutical interventions like physiotherapy, cognitive training, mental health support, and speech therapy. Patients often struggle to adhere to these multiple, disconnected programs.
Remepy’s "hybrid drug" model aims to collapse this fragmentation into a single, cohesive, and prescribable package. By leveraging the power of mobile devices, the company delivers, measures, and personalizes high-quality, non-pharmacological interventions that are mechanistically synchronized with the drug’s delivery.
"I think one reason nobody has done it before is that the digital therapeutic ecosystem had to evolve first," Tsur notes. "As technology advances and devices become more powerful, we can finally provide the level of clinical rigor that doctors demand."
Learning from the First Wave: The "Pear" Lesson
The development of Remepy was significantly informed by the high-profile commercial collapse of early pioneers in the digital therapeutics space. Most notably, Pear Therapeutics—the first company to secure FDA clearance for a prescription digital therapeutic—filed for Chapter 11 bankruptcy in 2023. Despite proving that doctors would prescribe their software and that patients would use it, the company could not navigate the treacherous waters of insurance reimbursement.
Remepy has taken a calculated, alternative path. By framing its products as "hybrid drugs"—integrating software into a regulatory and commercial framework alongside a proven pharmaceutical agent—the company is aiming to secure its place within the established pharma economy.
"We decided to invent this new type of product," Tsur says. "Everything is mechanistically and scientifically proven, and we take it through rigorous clinical trials. In the end, it is a drug and an app working in tandem."
This strategy relies heavily on the FDA’s "Prescription Drug Use-Related Software" (PDURS) pathway. By classifying the digital component as an integral part of the drug’s delivery and efficacy, Remepy is positioning itself to expand drug labels based on the combined clinical performance of the software and the medication.
Chronology of a Breakthrough: The Path to Hybridopa
The development of Hybridopa, the company’s flagship project for Parkinson’s disease, follows a rigorous, evidence-based timeline:
- Conceptualization: The founding team, including Or Shoval, Prof. Amir Amedi, Eran Etam, and Dr. Michal Tsur, identified Parkinson’s as a prime candidate for the hybrid model due to the high efficacy of levodopa and the clear, documented benefits of non-pharmacological therapies.
- Protocol Design: The team engineered "DopApp," a digital protocol designed to provide daily motor, speech, and cognitive exercises, while tracking real-time patient symptoms like stiffness and tremors.
- Phase IIa Initiation: A 41-patient, three-week double-blind study was launched to evaluate the impact of the hybrid approach.
- May 2026 Milestone: Remepy reported that the study met its primary endpoint, demonstrating that patients utilizing the DopApp in conjunction with their existing carbidopa-levodopa regimen experienced significant improvements in motor function.
- Publication: The data was subsequently published in Brain Communications, validating the methodology for the broader medical community.
Supporting Data: Doubling the Clinical Effect
The results of the Phase IIa trial were striking, particularly given the inherent limitations of standard Parkinson’s treatments. Levodopa, while the gold standard, has a well-documented "ceiling effect." As the disease progresses, the drug’s effectiveness tends to narrow, and motor fluctuations—often referred to as "on-off" periods—become increasingly difficult to manage.
In the 13-year cohort studies cited by the company, all patients typically experience motor fluctuations within a decade of treatment. Remepy’s goal was to push past this ceiling.
In the trial, patients were randomized to either receive the DopApp or a placebo app, while maintaining their existing dosages of carbidopa-levodopa. The results were clear:
- The Treatment Group: Patients using the full DopApp protocol showed an average improvement of 9.7 points on the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
- The Placebo Group: Patients using a placebo app showed an improvement of only 1.95 points.
- Response Threshold: A staggering 90% of the treated patients cleared the five-point response threshold, a key metric for clinical significance.
Dr. Tsur contextualizes these figures by noting that the drug alone typically reduces the MDS-UPDRS score by eight to ten points. By adding the digital protocol, Remepy essentially doubled the clinical impact of the medication. "For many drugs, there’s a ceiling effect you cannot go beyond without attaching these interventions," she explains.
Implications: The Future of Prescribable Digital Medicine
The implications of Remepy’s model extend far beyond Parkinson’s disease. By creating a platform that integrates multiple mechanisms—movement, speech, cognition, and mood—into a single, unified therapeutic package, the company is addressing the high degree of patient variation that often hinders traditional, single-mechanism drug development.
Clinical Efficiency
For the neurologist, the current burden of care is significant. A physician must prescribe a complex medication regimen and then provide separate referrals for physical therapy, speech therapy, and occupational therapy. These services are often siloed, leading to poor communication and lower patient adherence. Remepy’s hybrid drug offers a streamlined solution: "We’re making physicians’ lives easier because, instead of prescribing a drug and then recommending many other therapies, they just prescribe a hybrid drug."
Economic Sustainability
By aligning with the PDURS pathway, Remepy is solving the "reimbursement gap" that killed the first generation of digital health companies. Because the software is part of the drug package, it enters the existing pharmaceutical billing and distribution channels. This creates a more sustainable business model that satisfies both the payer and the healthcare provider.
Precision Medicine
The software component allows for unprecedented personalization. As the patient’s condition evolves, the AI-driven protocol can re-tune itself, adjusting the intensity and nature of the exercises to match the patient’s current functional status. This level of responsiveness is nearly impossible to achieve with a traditional, static pill-based prescription.
Conclusion: A New Standard of Care?
Remepy’s success with Hybridopa serves as a proof-of-concept for a new era of "intelligent" medicine. By bridging the divide between pharmaceutical science and digital intervention, the company is not merely adding an app to a patient’s phone—it is creating a more robust, personalized, and effective therapeutic entity.
While the journey from a Phase IIa trial to full-scale clinical adoption is long and demanding, the early data suggests that the "hybrid" approach may be the missing piece in the puzzle of chronic disease management. If successful, Remepy’s model could set the standard for how we approach complex neurological, immunological, and oncology indications, transforming the way we treat patients for decades to come.
The era of "there’s an app for that" has matured; the era of "there’s a hybrid drug for that" is just beginning.
About the Author
